Oxford BioDynamics PLC (LSE:OBD) - Share price

Stock Report

Oxford BioDynamics PLC OBD

Last Price

Day Change

As of 18/05/2022
16:35:31 BST | GBX
Minimum 15 Minutes Delay.

Last Close17.25p
Day Range16.88 - 17.56
Mkt Cap17.31Mil
52-Wk Range16.00 - 71.00
Yield %-

Share Price

Total Returns 17/05/2022

 Chg (%)  
More ...
Oxford BioDynamics PLC-16.87 
FTSE 100 TR GBP-1.00
More ...
Income Statement
Operating Profit-3.72-4.95-7.51
Net Profit-2.80-4.35-6.68
Reported EPS-3.00-4.70-7.20
Balance Sheet
Current Assets16.9212.886.68
Non Current Assets1.482.058.70
Total Assets18.4114.9315.38
Current Liabilities1.111.292.30
Total Liabilities1.201.778.69
Total Equity17.2113.166.69
Cash Flow
Operating Cash Flow-2.75-3.99-6.51
Net Change in Cash-13.221.00-3.90

Regulatory News

DateAuthor Headline
24/04/2019David Brenchley Are Dual-Class Share Structures Bad for Investors?
Some of the most-popular US technology stocks have dual-class share structures, which give founders disproportionate control. How should investors weigh up the pros and cons?
20/11/2018David Brenchley Which Stocks Did Managers Buy in October's Sell-Off?
As global stock markets continue to sell off, we asked fund managers which stocks they have either added to their portfolio or topped up their exposure to
15/10/2018David Brenchley ETF Investors Drop Commodity and Gold Funds
After inflows in the first half of 2018, commodity-focused exchange traded funds saw sentiment reverse in Q3 as investors took flight
Director Dealings
More ...
06/04/2022PurchaseMr. Stephen Charles Diggle18.80400,00075,200.00
06/04/2022PurchaseMr. Stephen Charles Diggle18.50200,00037,000.00
06/04/2022PurchaseMr. Paul Leslie Stockdale17.8030,0005,340.00
06/04/2022PurchaseMr. Matthew Anthony Wakefield18.9025,0004,725.00

Company Profile

Oxford BioDynamics PLC is a biotechnology company. The company focuses on the discovery and development of biomarkers for use within the pharmaceutical and biotechnology industry. It provides a technology platform Episwitch which aims to accelerate the drug discovery and development process and improve the success rate of therapeutic product development.




FTSE AIM All-Share

Next Event 15/06/2022

Half-Yearly Results
More ...
PER (E)0.00
Div Yld (E)0.00
PEG (E)0.00
Op Mrgn-22.03
EPS Grwth0.00
More ...
Record Datet.b.c.t.b.c.
More ...
Non-Executive DirectorDr. David Mark Anthony Holbrook
Executive Director, Chief Scientific OfficerDr. Alexandre Akoulitchev
Non-Executive DirectorMr. Stephen Charles Diggle
Executive Director, Chief Financial OfficerMr. Paul Leslie Stockdale
Executive Director, Group Chief Executive OfficerDr. Jon Anthony Joseph Burrows
Non-Executive Director, ChairmanMr. Matthew Anthony Wakefield
AJ Bell Management Limited (company number 03948391), AJ Bell Securities Limited (company number 02723420) and AJ Bell Asset Management Limited (company number 09742568) are authorised and regulated by the Financial Conduct Authority. All companies are registered in England and Wales at 4 Exchange Quay, Salford Quays, Manchester M5 3EE. See website for full details. AJ Bell procures the provision of the Morningstar Licensed Tools on an “as is” basis and does not guarantee the performance of or accept liability for the Licensed Tools. To the maximum extent permitted by law, AJ Bell excludes liability for the Licensed Tools, including liability for any failure, interruption, delay or defect in the performance of any Licensed Tool, unless it arises as a direct result of the negligence of AJ Bell.
© Copyright 2022 Morningstar. All rights reserved.